Factsheet as on April 30, 2026
 

Factsheet as on April 30, 2026

Nippon India Pharma Fund

Back
Back
Structure
Open Ended
Fund Category
Thematic/Sectoral
Fund Manager
Sailesh Raj Bhan, Amber Singhania, Kinjal Desai
Exit Load
Within 1 Month - 1%
Fund Size
Rs 8,365 crs
Launch Date
June 05, 2004

Investment Objective

To generate consistent returns by investing in equity or fixed income securities of pharma and other associated companies.


Market Cap Allocation



Scheme Performance

 1 Year2 Years3 Years5 Years
Scheme (%) 4.04 9.84 22.10 13.33
Nifty 500 (%) 2.97 3.94 14.19 12.90
Returns are CAGR

Top 10 Holdings

Company Name% of Assets
Sun Pharmaceutical Industries Ltd. 13.8
Lupin Ltd. 7.9
Dr Reddys Laboratories Ltd. 7.0
Divi Laboratories Ltd. 6.6
Cipla Ltd. 5.5
Apollo Hospitals Enterprise Ltd. 5.0
Medplus Health Services Ltd. 3.8
Vijaya Diagnostic Centre Ltd. 3.4
Ajanta Pharmaceuticals Ltd. 3.2
Sai Life Sciences Ltd. 3.3

Year On Year Performance (Scheme V/S Nifty 500)


Ratios:
Standard Deviation    15.61
Information Ratio     0.13
Beta     0.87
Sharpe Ratio     0.28

Top 5 Sectoral Holdings (%)

SIP Returns


Source: MFI Explorer, Bloomberg.
Please refer to the disclaimer and glossaries

Kotak Mahindra Bank Limited, AMFI Registered Mutual Fund Distributor, ARN 1390

Kotak Mahindra Bank Limited, AMFI Registered Mutual Fund Distributor, ARN 1390